Next Article in Journal
Obesity Drug Update: The Lost Decade?
Next Article in Special Issue
GPCR Conformations: Implications for Rational Drug Design
Previous Article in Journal
Allosteric Modulation of αβδ GABAA Receptors
Previous Article in Special Issue
Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development
Pharmaceuticals 2010, 3(11), 3478-3493; doi:10.3390/ph3113478

Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease

 and *
Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, FL 32610, USA
* Author to whom correspondence should be addressed.
Received: 21 September 2010 / Revised: 27 October 2010 / Accepted: 8 November 2010 / Published: 9 November 2010
(This article belongs to the Special Issue GPCR Based Drug Discovery)
View Full-Text   |   Download PDF [307 KB, uploaded 9 November 2010]   |  


Patients with hypertension often manifest a dysregulated renin-angiotensin-aldosterone system (RAAS). Most of the available treatment approaches for hypertension are targeted towards the RAAS including direct renin inhibition, ACE inhibition, angiotensin II type 1 receptor (AT1-R) blockade, and aldosterone receptor antagonism. The Jak2 signaling pathway is intricately coupled to the AT1-R signaling processes involved in hypertension. Here, we review the involvement of Jak2 in the pathogenesis of hypertension, and its potential as a therapeutic target for treatment of AT1-R mediated cardiovascular disease. Jak2 may provide a rational therapeutic approach for patients whose blood pressure is not controlled by standard therapies.
Keywords: angiotensin II; Jak2; AT1-receptor; hypertension angiotensin II; Jak2; AT1-receptor; hypertension
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Kirabo, A.; Sayeski, P.P. Jak2 Tyrosine Kinase: A Potential Therapeutic Target for AT1 Receptor Mediated Cardiovascular Disease. Pharmaceuticals 2010, 3, 3478-3493.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert